Molecular mechanisms of resveratrol and its silver nanoparticle conjugate in addressing sepsis-induced lung injury
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-024-03058-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Hilal Üstündağ und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, 2400, Türkiye. hurcar@gmail.com. Hauptthemen laut MEDLINE: Resveratrol, Sepsis, Metal Nanoparticles, Silver. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erzincan Binali Yildirim University.
Themen: Sepsis
Abstract (Originalsprache)
Sepsis is a life-threatening condition characterized by a systemic inflammatory response to infection. Despite extensive research on its pathophysiology, effective therapeutic approaches remain a challenge. This study investigated the potential of resveratrol (RV) and silver nanoparticle–enhanced resveratrol (AgNP-RV) as treatments for sepsis-induced lung injury using a rat model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). The study focused on evaluating changes in oxidative status (TAS, TOS, and OSI) and the expression of inflammatory and apoptotic markers (IL-1β, TNF-α, P2X7R, TLR4, Caspase-3, and Bcl-2) in lung tissue. Both RV and AgNP-RV demonstrated potential in mitigating oxidative stress, inflammation, and apoptosis, with AgNP-RV exhibiting greater efficacy than RV alone ( p < 0.05). These findings were corroborated by histopathological analyses, which revealed reduced tissue damage in the RV- and AgNP-RV-treated groups. Our study highlights the therapeutic potential of RV and, particularly, AgNP-RV in combating sepsis-induced oxidative stress, inflammation, and apoptosis. It also underscores the promise of nanoparticle technology in enhancing therapeutic outcomes. However, further investigations are warranted to fully understand the mechanisms of action, especially concerning the role of the P2X7 receptor in the observed effects. Nonetheless, our research suggests that RV and AgNP-RV hold promise as novel strategies for sepsis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, 2400, Türkiye. hurcar@gmail.com.
- Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum, Türkiye.
- Department of Physiology, Faculty of Medicine, Sakarya University, Sakarya, Türkiye.
- Department of Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Türkiye.
- Department of Veterinary Histology and Embryology, Faculty of Veterinary Medicine, Veterinary Medicine Basic Sciences, Erzurum, Türkiye.
- Department of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, 2400, Türkiye.
Förderung
- Erzincan Binali Yildirim University
Zitieren
APA
Üstündağ, H., Kara, A., Doğanay, S., Kurt, N., Erbaş, E., Kalindemirtaş, F. D., & Kariper, İ. A. (2024). Molecular mechanisms of resveratrol and its silver nanoparticle conjugate in addressing sepsis-induced lung injury. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03058-y
Vancouver
Üstündağ H, Kara A, Doğanay S, Kurt N, Erbaş E, Kalindemirtaş FD, et al. Molecular mechanisms of resveratrol and its silver nanoparticle conjugate in addressing sepsis-induced lung injury. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03058-y
BibTeX
@article{stnda2024,
author = {Üstündağ, Hilal and Kara, Adem and Doğanay, Songül and Kurt, Nezahat and Erbaş, Elif and Kalindemirtaş, Ferdane Danişman and Kariper, İshak Afşin},
title = {Molecular mechanisms of resveratrol and its silver nanoparticle conjugate in addressing sepsis-induced lung injury},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-024-03058-y}
}
EUVIMED